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INTRODUCTION
Prostate Imaging-Reporting and Data System Version 2 
(PI-RADSv2) is a language of prostate magnetic resonance 
imaging (MRI) for communicating the probability of 
clinically significant prostate cancer (csPCa). PI-RADSv2 
scoring uses a 5-point Likert scale to assess csPCa, and 
study data have suggested that a score of 4 or greater 
indicates a high probability of csPCa (1, 2). The pooled 
sensitivity and specificity were 85−89% and 71−73%, 
respectively (2, 3).
In terms of estimating the likelihood of PCa, PI-RADSv2 
scores are somewhat similar to prostate-specific antigen 
(PSA). The probability of PCa increases as the serum PSA level 
increases (e.g., < 4; 4−10; and ≥ 10) (4). Likewise, in recent 
Prostate Imaging-Reporting and Data System Version 2: 
Beyond Prostate Cancer Detection 
Sung Yoon Park, MD1, Nam Hoon Cho, MD2, Dae Chul Jung, MD1, Young Taik Oh, MD1
Departments of 1Radiology and 2Pathology, Yonsei University College of Medicine, Seoul 03722, Korea
The main purpose of Prostate Imaging-Reporting and Data System Version 2 (PI-RADSv2) is to effectively detect clinically 
significant prostate cancers (csPCa) using multiparametric magnetic resonance imaging. Since the first introduction of PI-
RADSv2, researchers have validated its diagnostic performance in identifying csPCa, and these promising data have 
influenced biopsy and treatment schemes. However, in this article, we focused on the potential of PI-RADSv2 in relation to 
various aspects of PCa such as Gleason score, tumor volume, extraprostatic extension, lymph node metastasis, and postoperative 
biochemical recurrence, beyond prostate cancer detection.
Keywords: PI-RADS; Prostate cancer; Magnetic resonance imaging; Recurrence; Prognosis
Received July 26, 2017; accepted after revision October 2, 2017.
Corresponding author: Young Taik Oh, MD, Department of 
Radiology, Yonsei University College of Medicine, 50 Yonsei-ro, 
Seodaemun-gu, Seoul 03722, Korea.
• Tel: (822) 2228-7400 • Fax: (822) 393-3035
• E-mail: oytaik@yuhs.ac
This is an Open Access article distributed under the terms of 
the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/4.0) which permits 
unrestricted non-commercial use, distribution, and reproduction in 
any medium, provided the original work is properly cited. 
studies, the detection rates of PCa increased sequentially 
according to PI-RADSv2 scores (5, 6). This situation indicates 
that PI-RADSv2 may provide guidelines with respect to 
further investigations such as biopsy, like PSA.
Prostatic lesions showing higher PI-RADSv2 scores are 
more likely to be proven as csPCa by targeted biopsy (7). 
Meanwhile, for the lesions with scores less than 3, an 
additional targeted biopsy may not be necessary because 
of low cancer detection rate (8). Also, the application of 
PI-RADSv2 may reduce the total number of biopsy cores. 
A previous study demonstrated comparable diagnostic 
performance between two-core targeted biopsy using PI-
RADSv1 from prebiopsy MRI and 12-core systematic biopsy 
in detecting csPCa (9). For biopsy-proven low-grade PCa, 
PI-RADSv2 from postbiopsy MRI may aid in reducing the 
risk of underestimation by predicting the risk of Gleason 
score (GS) upgrading (10). This would aid in the decision 
regarding optimal management.
In PI-RADSv2, the lesions with higher scores, suggestive 
of csPCa, are likely to be apparently visible and/or large on 
multiparametric MRI (mpMRI) or surgical specimen. These 
radiologic and pathologic characteristics are inevitably 
associated with aggressiveness or prognosis of PCa (11, 
12). Here, we will discuss the potential roles of PI-RADSv2 
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in assessing various aspects of PCa beyond its primary role 
in csPCa detection.
PI-RADSv2 Scoring and MRI Protocols
For PI-RADSv2 scoring, mpMRI consists of diffusion-
weighted imaging (DWI) with/without dynamic contrast-
enhanced (DCE) MRI for evaluating peripheral zone (PZ), 
and T2-weighted imaging (T2WI) with/without DWI for 
evaluating transition zone (TZ) (13). When the finding of 
the primary MR sequence is indeterminate for csPCa (e.g., 
a score of 3), findings of the secondary MR sequence (e.g., 
focal early enhancement in the DWI-suspected PZ lesion; 
focal areas of restricted diffusion, measuring 1.5 cm or 
greater, in the T2WI-suspected TZ lesion) can determine 
a final score of 3 or 4. The final PI-RADSv2 score using 
a 5-point scale is not for detecting every PCa, but for 
estimating the probability of csPCa.
It is recommended that some parameters of the essential 
MR sequences for scoring (e.g., T2WI, DWI, and DCE MRI) 
should be similar because they often have a complementary 
role in lesion characterization in the same prostatic region 
(14). At our institution, the field-of-view is uniformly 20 
cm, and the slice thickness is 4 mm or less for the three MR 
sequences.
For acquiring an apparent diffusion coefficient (ADC) 
map, the monoexponential fit with the lowest b-value of 
50−100 s/mm2 and the highest b-value of 800−1000 s/
mm2 is appropriate. For analyzing high b-value DW images, 
PI-RADSv2 recommends image acquisition at a b-value of 
1400−2000 s/mm2 by means of either a direct or synthetic 
method because of better lesion conspicuity without 
significant loss of signal-to-noise ratio (15, 16).
In DCE MRI, a temporal resolution of 7 seconds or less is 
preferred to assess focal, early enhancement in the prostate 
gland (13). Semi-quantitative or quantitative analyses 
of DCE MRI using dedicated software are optional. T1-
weighted imaging (T1WI) is also recommended to evaluate 
post-biopsy hemorrhage, delineate the gland, and detect 
lymph node (LN) or skeletal metastases although it is not 
integrated into the process of PI-RADSv2 scoring. The MRI 
protocols required for PI-RADSv2 interpretation have been 
well summarized in a previous review article (14).
Beyond Cancer Detection
Gleason Score
Analysis of DWI enables assessment of histologic tumor 
aggressiveness (17). Because the degree of restricted 
diffusion reflects the architectural distortion of the 
extracellular space and tumor cellularity (18), PCa with 
higher GS typically manifests as a focal hyperintense lesion 
on high b-value DWI with low ADC value. Hence, there is 
an inverse correlation between tumor ADC and GS. In visual 
analysis of DWI, lesion conspicuity is greatly affected by 
differences in restricted diffusion between cancerous and 
benign tissues (19). Thus, PCa with higher GS and diffusion 
restriction shows good lesion conspicuity on DWI.
In PI-RADSv2, DWI is a major MR sequence for PZ 
evaluation, and it also determines the likelihood of csPCa 
when the findings of T2WI are equivocal for TZ (e.g., a T2WI 
score of 3) (13). Therefore, PI-RADSv2 scores are closely 
associated with lesion conspicuity on DWI. Based on this 
background, a certain degree of relationship among the 
A B C D
Fig. 1. 69-year-old man with serum PSA level of 18.6 ng/mL and biopsy-proven GS 6 PCa.
A. T2WI showed focal hypointense area in anterior TZ of prostate gland (arrow). PI-RADSv2 score on T2WI was 5. B, C. High b-value DWI and ADC 
map consistently showed focal area of diffusion restriction at corresponding site (arrow). Final PI-RADSv2 score on DWI was 5. Thus, final PI-RADSv2 
score was 5 for TZ lesion. D. In surgical specimen, GS 7 PCa was confirmed (dotted area). This is case of GS upgrading, which was suspected by PI-
RADSv2. ADC = apparent diffusion coefficient, DWI = diffusion-weighted imaging, GS = Gleason score, PCa = prostate cancer, PI-RADSv2 = Prostate 
Imaging-Reporting and Data System Version 2, PSA = prostate-specific antigen, TZ = transition zone, T2WI = T2-weighted imaging
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degree of diffusion restriction, PI-RADSv2 scores, and GS 
is expected. In recent studies, PI-RADSv2 scores showed a 
positive correlation with GS (20). This helps PI-RADSv2 to 
verify the biopsy results (10, 21) (Fig. 1).
However, it is still uncertain which MR parameter is better 
correlated with GS. Basically, the interval of PI-RADSv2 
scores is much greater than that of ADC values. Therefore, 
a particular score of PI-RADSv2 may comprise various 
ranges of GS (1) (Fig. 2). Conversely, there also may be a 
significant overlap of GS between neighboring PI-RADSv2 
scores. For determining whether the PI-RADSv2 score is 4 
or 5, the lesion size is an important factor (e.g., 1.5 cm). 
Thus, for GS 7 or greater PCa, the PI-RADSv2 score can be 4 
when the tumor is small, while the score can be 5 when the 
tumor is large. Further studies are required to confirm which 
parameter better represents GS.
Tumor Volume
A tumor volume of 0.5 cm3 is the most commonly applied 
threshold to determine csPCa (22). However, mpMRI is 
inadequate for detecting small PCa. Tumor volume less than 
1.0 cm3 is often associated with false negative diagnosis 
by means of mpMRI (23, 24). In addition, there are many 
benign mimickers in the prostate gland simulating PCa such 
as focal inflammation, stromal hyperplasia, central zone, 
anterior fibromuscular stroma, or surgical capsule (25). 
Thus, in case of a small PCa, there is a risk of false positive 
diagnosis by using mpMRI (e.g., a false diagnosis of the 
anterior fibromuscular stroma as a large anterior TZ PCa).
Vargas et al. (26) reported that more than 50% of PCa 
with GS 4 + 3 or greater were underestimated by PI-RADSv2 
when the tumor volume is less than 0.5 cm3. Seo et al. 
(10) reported that more than half of the underestimated 
cases (e.g., PI-RADSv2 score less than 4 for csPCa) had 
tumor volume less than 1.0 cm3. Based on these data, there 
may be a discrepancy in the cutoff value of tumor volume 
between MR detectability and Epstein criteria (Fig. 3).
Multiparametric magnetic resonance imaging may also 
A B C D
Fig. 2. DWI and ADC maps of two different patients.
A, B. 53-year-old man with serum PSA level of 7.6 ng/mL and PCa. High b-value DWI and ADC map showed focal area of diffusion restriction, 
measuring 0.9 cm, in left PZ of prostate gland (arrow). DWI and final PI-RADSv2 scores were 4 each. Mean tumor ADC was 0.91 x 10-3 mm2/s. 
Surgery revealed GS 6 PCa. C, D. 65-year-old man with serum PSA level of 13.2 ng/mL and PCa. High b-value DWI and ADC map showed focal area 
of diffusion restriction, measuring 1.0 cm, in left PZ of prostate gland (arrow). DWI and final PI-RADSv2 scores were 4 each. Mean tumor ADC was 
0.71 x 10-3 mm2/s. Surgery revealed GS 7 PCa. These are cases of PCa with different GS, whose PI-RADSv2 scores were same, but tumor ADCs were 
different. PZ = peripheral zone
A B C D
Fig. 3. 67-year-old man with serum PSA level of 22.4 ng/mL and PCa.
A, B. High b-value DWI and ADC map showed focal, indistinct area of mild diffusion restriction in right PZ of prostate gland (arrow). DWI score 
was 2. C. DCE MRI showed diffuse, gradual enhancement around corresponding site (arrow), which is suggestive of negative findings. Thus, 
final PI-RADSv2 score on DWI was 2 for PZ lesion. D. In surgical specimen, GS 6 PCa with tumor volume of 0.8 cm3 was confirmed (dotted area). 
According to Epstein criteria, this is case of csPCa underestimated by PI-RADSv2. CsPCa = clinically significant prostate cancer, DCE = dynamic 
contrast-enhanced, MRI = magnetic resonance imaging
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have a limitation in detecting sparse PCa. Sparse PCa 
consist of a mixture of scattered cancer cells and normal PZ 
tissues (27). Therefore, the volume of cancer cells in sparse 
PCa is inevitably smaller than that in dense PCs within 
the same region. Accordingly, it is expected that sparse 
PCa cannot be easily differentiated from adjacent normal 
prostatic tissues. Langer et al. (27) reported that ADC and 
T2 values of sparse PCas are similar to those of normal PZ 
tissues.
Based on these data, it should be determined whether 
the current Epstein criteria (1) GS > 3 + 3; 2) tumor volume 
≥ 0.5 cm3; or 3) presence of extraprostatic extension [EPE]), 
especially for the tumor volume, are indeed the appropriate 
goal of PI-RADSv2, or they need to be changed: for 
example, 1) GS 3 + 3 PCa with tumor volume ≥ 1.0 cm3 or 
GS ≥ 3 + 4 PCa with any volume, or 2) only GS ≥ 3 + 4 PCa. 
Clinically, there is a debate regarding the tumor volume 
threshold for defining csPCa (28-30).
Extraprostatic Extension
Extraprostatic extension is a well-established adverse 
prognostic factor in PCa (31). Thus, radiologic investigation 
for EPE is important in terms of predicting the prognosis 
and surgical planning. The MR findings of organ-confined 
PCa may lead to a nerve-sparing approach in surgery 
(32). Conversely, a more wide excision may be required to 
secure the safety margins when EPE is highly suspected. 
In prostate MRI, T2WI is the mainstay for assessing EPE 
because of its high spatial resolution (13, 33). 
The imaging criteria for EPE suggested in PI-RADSv2 
are as follows (13): 1) asymmetry or invasion of the 
neurovascular bundles, 2) a bulging prostatic contour, 3) 
irregular or spiculated margin, 4) obliteration of the recto-
prostatic angle, 5) a tumor-capsule interface of greater than 
1 cm, or 6) breach of the capsule with evidence of direct 
tumor extension or bladder wall invasion. In PI-RADSv2, the 
findings of definite EPE on a major MR sequence (e.g., DWI 
for PZ and T2WI for TZ) lead to a final score of 5. 
In a previous study conducted by Kayat Bittencourt et al. 
(34), the analysis of a major MR sequence alone allowed 
comparable performance with combined analysis of mpMRI 
for EPE. Another study demonstrated that a score of 5 
showed higher rates of EPE than a score of 4 (48.7% vs. 
11.5%; p < 0.001) (35). Krishna et al. (36) also found that 
the rate of EPE sequentially and significantly increased 
according to PI-RADSv2 scores. These data indicate that PI-
RADSv2 has the potential to assess the risk of EPE.
However, there may be controversy regarding the 
imaging criteria for ‘definite’ EPE because the degree of 
suspicion may be relatively different for each MR criterion. 
For example, measurable extracapsular extension may be 
a stronger indicator than findings of capsular abutment 
or irregularity caused by cancer (37). Also, MR findings 
of subtle capsular or extracapsular changes could be 
inconsistently interpreted depending on the discretion of 
radiologists (Figs. 4, 5). Furthermore, integrating T2WI 
in the evaluation of EPE is somewhat discordant with the 
dictionary definition of ‘definite EPE on DWI’ when PZ is 
evaluated. More discussions regarding the definition of 
‘definite EPE’ may be required as the current PI-RADSv2 
only provides various imaging findings of EPE without any 
specific grading system for each finding unlike the initial 
version of PI-RADS.
A B C D
Fig. 4. 54-year-old man with serum PSA level of 6.2 ng/mL and PCa.
A, B. High b-value DWI and ADC map showed focal area of marked diffusion restriction, measuring 1.5 cm, in right PZ of prostate gland 
(arrow). Overt protrusion of lesion into right extraprostatic area was also seen. DWI score was consistently 5 as measured by two independent, 
experienced radiologists. C. T2WI also demonstrated focal hypointense lesion with high suspicion of right EPE (arrow). Thus, final PI-RADSv2 
score on DWI was also consistently 5 for PZ lesion as measured by two independent, experienced radiologists. D. In surgical specimen, GS 8 PCa 
with right EPE was confirmed (dotted area). EPE = extraprostatic extension
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Lymph Node Metastasis
The status of pelvic LNs influences treatment planning. 
However, the currently available most optimal method for 
LN assessment is surgical LN dissection (32). Radiologically, 
pelvic LN metastases in PCa are often small (38). Thus, 
the use of the classical size criterion (e.g., 0.8−1.0 cm in 
short-axis diameter) alone is associated with the risk of 
underestimation in LN assessment (39, 40).
Previous studies have shown great promise in terms of 
advanced LN imaging: 1) MRI using ultra-small particles 
of iron oxide or 2) choline-based or prostate specific 
membrane antigen-based positron emission tomography 
scan (41-45). However, these techniques have not been 
utilized at every institution (46). Therefore, the selection 
of optimal candidates to maximize the effectiveness 
of advanced imaging or pelvic LN dissection (PLND) is 
important in daily practice, as it reduces the medical cost 
or morbidity.
In practice, various clinical nomograms aid in selecting 
the patients who need PLND. The parameters used in 
nomograms are usually PSA, clinical stage, and biopsy 
information including GS and tumor burden (47-49). 
Thus, the status of the primary lesion is closely related 
to the nodal status (11, 50). However, these parameters 
(e.g., stage, GS, or tumor burden) do not directly provide 
information regarding the anatomical status of PCa, thus 
miscalculation of the risk can occur (51).
As discussed earlier, PI-RADSv2 scores are associated 
with the status of GS, tumor volume, and EPE of PCa. Thus, 
there may be a certain degree of relationship between PI-
RADSv2 scores and risk of pelvic LN metastasis. A recent 
study demonstrated that PSA, GS, and tumor stage were 
significantly different between patients with a score of 5 
and the other patients (52). In the study, a cutoff score 
of 5 provided a positive predictive value of approximately 
A B C D
Fig. 5. 44-year-old man with serum PSA level of 22.0 ng/mL and PCa.
A, B. High b-value DWI and ADC map showed focal area of marked diffusion restriction, measuring 1.1 cm, in right PZ of prostate gland (arrow). 
Broad tumor-capsule contact was also seen. DWI score was 4 and 5 as measured by two independent, experienced radiologists, respectively, due 
to different interpretation regarding definite EPE. C. T2WI also demonstrated focal hypointense lesion with broad tumor-capsule contact (arrow). 
Thus, final PI-RADSv2 score on DWI was also 4 and 5 as measured by two independent, experienced radiologists, respectively. D. In surgical 
specimen, GS 7 PCa without EPE was confirmed (dotted area).
A B C D
Fig. 6. 69-year-old man with serum PSA level of 19.7 ng/mL and PCa.
A, B. High b-value DWI and ADC map showed focal area of marked diffusion restriction, measuring 1.8 cm, in right PZ of prostate gland (arrow). 
Overt protrusion of lesion into right extraprostatic area was also seen. DWI score was 5. C. DCE MRI also showed positive findings (arrow). Thus, 
final PI-RADSv2 score was 5. D. In surgical specimen, GS 9 PCa with right EPE was confirmed (dotted area). In this patient, normal-sized (e.g., 
short-axis diameter < 0.8 cm) pelvic lymph node metastasis was proven surgically.
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20%, while the negative predictive value was roughly 99% 
for normal-sized LN metastasis (Fig. 6). Therefore, the 
authors suggested that PI-RADSv2 may help predict a very 
low risk group for LN metastasis. Prospective validation is 
necessary for practical application.
Postoperative Biochemical Recurrence
Literatures have suggested that mpMRI may predict 
post-treatment prognosis following surgical (12) or non-
surgical (53) treatment. Apparently visible lesions are more 
likely to be aggressive PCa with worse clinical outcomes, 
compared with PCa with poor lesion conspicuity. Zhang et 
al. (54) reported that PI-RADS version 1 was independently 
associated with time to biochemical recurrence (BCR), 
and adding the MR parameters to the clinical nomogram 
significantly increased the performance. Park et al. (20) 
reported that the 2-year BCR-free survival rates were 
significantly different among three PI-RADSv2 subgroups 
(approximately, 100% for patients with score 1−3; 90% for 
patients with score 4; and 70% for patients with score 5). 
This might be because various pathologic conditions of an 
index tumor or the risk of nodal invasion is reflected in PI-
RADSv2. From this point of view, PI-RADSv2 may be one 
of the useful predictors for postoperative BCR. Long-term 
follow-up data and combined analysis of PI-RADSv2 scores 
with clinical parameters are currently necessary.
CONCLUSION
Prostate Imaging-Reporting and Data System Version 
2 is an emerging tool for interpreting prostate MRI and 
it needs further validation regarding various aspects of 
PCa. Nevertheless, the data so far are promising. Based 
on the data discussed in this article, PI-RADSv2 seems to 
reflect tumor GS, tumor volume, EPE, nodal status, and 
postoperative BCR. Combined analysis of PI-RADSv2 scores 
with clinical parameters may maximize its effectiveness 
and may help in management planning. Therefore, as a 
non-invasive tool, PI-RADSv2 may play a role in evaluating 
various aspects of PCa as well as in detecting csPCa.
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